Scientists are making exciting strides in the fight against heart disease through gene-editing treatments. In a recent study, just one infusion significantly lowered cholesterol levels in patients with genetically high LDL cholesterol. If larger studies support these findings, this could lead to a one-time solution for many at risk of heart disease.
Heart disease is no small issue; it claims nearly 800,000 lives in the U.S. each year. Many experts believe that new treatments could change how we approach this problem. Dr. John H. P. Alexander, a cardiologist at Duke University, remarked, “A curative therapy would change the game.”
This study, published in The New England Journal of Medicine, involved 35 patients and will expand to 200 in the next phase. Remarkably, some patients saw LDL levels drop by as much as 62% after one treatment. The success of this trial is significant because it applies cutting-edge technology to a leading cause of death in America.
Dr. Eric Rubin, the journal’s editor, noted, “It looks like it works pretty well.” However, experts stress the importance of more safety data, as the FDA requires long-term follow-up for gene therapy studies.
The treatment uses a “machine” that travels through the bloodstream to the liver. There, it edits a specific gene, PCSK9, which plays a key role in cholesterol management. By altering one DNA letter in the gene, the liver can effectively lower LDL levels.
Dr. Sekar Kathiresan, who led the study, has personal reasons for his work. He lost family members to heart disease and is dedicated to finding effective solutions. Unlike typical gene therapies that cost millions, his team aims to make this treatment a part of everyday healthcare.
Current options for lowering cholesterol include statins, but many people struggle with adherence. Around 30-50% of patients stop taking their medications within a year, even after serious heart issues. Kristy Faulkner, a 45-year-old patient, understands the importance of treatment but feels a disconnect. “I can’t be on these meds every day of my life,” she said.
For patients like Alice Thomas, 64, this gene-editing approach could be life-changing. She struggled with high cholesterol and couldn’t tolerate traditional medications. After participating in the study, her cholesterol dropped dramatically just weeks later. “This is great,” she exclaimed. “One time and it’s over.”
As the trials continue, the hope is that this gene-editing treatment can become a standard option for those at risk, simplifying care and potentially saving countless lives.
For more information on heart disease and cholesterol management, you can check out resources from the CDC.
Source link
Heart,Cholesterol,Genetic Engineering,Genetics and Heredity,Research,Medicine and Health,Preventive Medicine,Eli Lilly and Company,New England Journal of Medicine
